LncRNA OR2A1-AS1 index predicts survival in germinal center-like diffuse large B-cell lymphoma

J Clin Lab Anal. 2022 Oct;36(10):e24680. doi: 10.1002/jcla.24680. Epub 2022 Sep 4.

Abstract

Background: Diffuse large B-cell lymphoma (DLBCL) is a highly aggressive form of non-Hodgkin lymphoma. Long noncoding RNA (lncRNA) has been evaluated as prognostic markers in various carcinomas. However, the prognostic value of the lncRNA index in DLBCL has not been fully understood. Hence, this study aimed to identify the prognostic value of lncRNA olfactory receptor family 2 subfamily A member 1-antisense RNA 1 (OR2A1-AS1) in DLBCL.

Methods: The Gene Expression Omnibus (GEO) database was used to obtain the GSE97336 dataset comprising lncRNA expression profiles. Quantitative reverse transcription polymerase chain reaction (QRT-PCR) was conducted to evaluate the expression of OR2A1-AS1 in 98 cases of DLBCL.

Results: OR2A1-AS1 expression was considerably reduced in DLBCL patients, reduced OR2A1-AS1 expression was linked to a shorter overall survival (OS) and progression-free survival (PFS) in DLBCL patients, especially those with the germinal center B-cell-like subtype (GCB). Multivariate analysis (MVA) revealed that the OR2A1-AS1 index had prognostic significance. Patients with low OR2A1-AS1 expression have a poor prognosis.

Conclusions: OR2A1-AS may represent an effective predictor of patients' outcomes with DLBCL.

Keywords: DLBCL; OR2A1-AS1; lncRNA.

MeSH terms

  • Disease-Free Survival
  • Germinal Center / metabolism
  • Germinal Center / pathology
  • Humans
  • Lymphoma, Large B-Cell, Diffuse* / metabolism
  • Prognosis
  • RNA, Antisense
  • RNA, Long Noncoding* / genetics
  • Receptors, Odorant*

Substances

  • RNA, Antisense
  • RNA, Long Noncoding
  • Receptors, Odorant